Insider Trading activities of Theravance Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Theravance Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Theravance Inc since year 2005. Table 2 shows the detailed insider transactions of Theravance Inc since 2005. The reporting company's ticker symbol is INVA. The reporting company's CIK number is 1080014.
The total value of stock buying since 2005 is $366,312,513,684,294.
The total value of stock sales since 2005 is $65,679,957.
The total value of stock option exercises since 2005 is $28,113,268.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Theravance Inc (INVA).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-08 0 $0 1,825 $22,265 0 $0
2017-05 0 $0 9,640 $115,484 0 $0
2017-02 0 $0 1,825 $22,027 0 $0
2016-11 0 $0 5,500 $59,724 0 $0
2016-08 0 $0 3,700 $43,549 0 $0
2016-05 0 $0 813 $8,512 0 $0
2015-08 245,828 $856,917,331,181 0 $0 0 $0
2015-06 0 $0 2,438 $41,080 0 $0
2015-05 85,579 $117,180,243,856 16,313 $266,228 16,313 $219,409
2015-03 92,674 $155,107,773,184 0 $0 0 $0
2014-11 832,456 $10,644,218,756,136 0 $0 0 $0
2014-08 172,651 $675,457,614,370 81,580 $1,825,038 108,108 $1,413,366
2014-05 317,770 $2,715,292,313,281 0 $0 0 $0
2014-04 0 $0 0 $0 51,612 $500,016
2014-03 0 $0 65,806 $2,433,176 216,344 $2,286,132
2014-02 342,229 $4,397,881,850,959 35,000 $1,387,750 0 $0
2013-10 130,473 $641,093,852,434 0 $0 0 $0
2013-09 0 $0 22,353 $894,790 0 $0
2013-08 0 $0 0 $0 18,750 $300,000
2013-07 3,064,407 $342,756,544,550,188 7,000 $255,570 0 $0
2013-06 0 $0 31,038 $1,087,571 0 $0
2013-05 0 $0 36,066 $1,344,605 43,279 $1,112,022
2013-04 193,563 $1,296,720,236,277 450,515 $15,322,947 564,373 $6,843,128
2013-02 116,527 $299,135,274,289 7,000 $154,980 0 $0
2013-01 0 $0 0 $0 14,510 $44,981
2012-11 280,348 $1,756,598,274,674 7,000 $153,825 5,161 $15,999
2012-08 316,334 $8,923,782 312,831 $8,625,645 316,039 $2,807,646
2012-05 10,000,000 $212,890,000 28,586 $632,202 63,225 $404,323
2012-02 88,468 $1,603,040 0 $0 0 $0
2011-12 0 $0 10,000 $218,600 0 $0
2011-11 58,411 $1,298,476 24,293 $510,153 30,205 $257,648
2011-09 0 $0 0 $0 3,225 $27,493
2011-06 0 $0 83,476 $1,931,334 0 $0
2011-05 261,299 $6,689,254 237,058 $6,148,464 103,253 $943,767
2011-03 0 $0 143,530 $3,217,009 58,344 $321,535
2011-02 152,278 $3,608,988 527,777 $11,561,794 784,944 $6,691,644
2011-01 0 $0 0 $0 9,838 $83,868
2010-12 0 $0 35,377 $909,743 26,029 $139,029
2010-11 5,750,000 $129,375,000 0 $0 0 $0
2010-09 0 $0 6,396 $86,638 6,451 $54,994
2010-06 0 $0 67,032 $1,042,347 67,032 $571,446
2010-02 12,702 $133,015 0 $0 32,258 $275,160
2009-12 0 $0 1,956 $25,447 200,000 $1,705,999
2009-09 0 $0 9,000 $160,704 9,000 $76,725
2008-07 0 $0 34,676 $553,671 0 $0
2008-06 0 $0 20,000 $260,693 20,000 $146,900
2008-03 105,085 $1,091,910 0 $0 0 $0
2007-12 0 $0 4,439 $100,498 54,310 $385,818
2007-10 0 $0 25,000 $625,000 0 $0
2007-09 0 $0 3,623 $100,154 0 $0
2007-08 0 $0 58,500 $1,561,954 10,000 $85,250
2007-06 0 $0 2,986 $100,287 0 $0
2007-02 0 $0 3,100 $99,014 0 $0
2006-06 0 $0 31,128 $752,103 23,007 $71,320
2006-05 0 $0 10,645 $303,020 51,406 $327,650
2005-12 0 $0 33,840 $714,362 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Theravance Inc insiders (INVA)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-08-21 Desparbes Eric (SVP and CFO) Sale 1,825 12.20 22,265
2017-05-22 Desparbes Eric (SVP and CFO) Sale 1,825 11.85 21,626
2017-05-22 Witek Theodore J. Jr. (Sr. VP & Chief Scientific Off.) Sale 7,815 12.01 93,858
2017-02-21 Desparbes Eric (SVP and CFO) Sale 1,825 12.07 22,027
2016-11-22 Witek Theodore L Jr (Sr. VP & Chief Scientific Off.) Sale 3,700 10.84 40,122
2016-11-21 Desparbes Eric (SVP and CFO) Sale 1,800 10.89 19,602
2016-08-22 Desparbes Eric (SVP and CFO) Sale 3,700 11.77 43,549
2016-05-18 Tyree James L Sale 813 10.47 8,512
2015-08-07 Glaxosmithkline Plc Buy 245,828 3,485,841.04 856,917,331,181
2015-06-02 Tyree James L Sale 2,438 16.85 41,080
2015-05-27 Waltrip William H Sale 16,313 16.32 266,228
2015-05-27 Waltrip William H Option Ex 16,313 13.45 219,409
2015-05-11 Glaxosmithkline Plc Buy 85,579 1,369,264.00 117,180,243,856
2015-03-02 Glaxosmithkline Plc Buy 92,674 1,673,692.44 155,107,773,184
2014-11-04 Glaxosmithkline Plc Buy 832,456 12,786,524.16 10,644,218,756,136
2014-08-13 Lee Junning (Sr. VP, Technical Operations) Sale 53,424 22.50 1,202,040
2014-08-13 Lee Junning (Sr. VP, Technical Operations) Option Ex 74,441 12.41 924,185
2014-08-12 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 1,048 22.30 23,370
2014-08-11 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 27,108 22.12 599,628
2014-08-11 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Option Ex 33,667 14.53 489,181
2014-08-11 Glaxosmithkline Plc Buy 172,651 3,912,271.66 675,457,614,370
2014-05-09 Glaxosmithkline Plc Buy 317,770 8,544,835.30 2,715,292,313,281
2014-04-17 Gunderson Robert V Jr Option Ex 25,806 9.69 250,008
2014-04-07 Young William D Option Ex 25,806 9.69 250,008
2014-03-31 Waltrip William H Option Ex 25,806 9.69 250,008
2014-03-21 Levine Arnold J Option Ex 25,806 9.69 250,008
2014-03-06 Mammen Mathai (SVP, Research & Early Clin Dev) Option Ex 42,153 14.20 598,572
2014-03-06 Whitesides George M Option Ex 25,806 9.69 250,008
2014-03-03 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 65,806 36.98 2,433,176
2014-03-03 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Option Ex 96,773 9.69 937,536
2014-02-14 Mammen Mathai (SVP, Research & Early Clin Dev) Sale 35,000 39.65 1,387,750
2014-02-11 Glaxosmithkline Plc Buy 342,229 12,850,698.95 4,397,881,850,959
2013-10-29 Glaxosmithkline Plc Buy 130,473 4,913,613.18 641,093,852,434
2013-09-12 Winningham Rick E (Chief Executive Officer) Sale 22,353 40.03 894,790
2013-08-21 Mammen Mathai (SVP, Research & Early Clin Dev) Option Ex 18,750 16.00 300,000
2013-07-30 Mammen Mathai (SVP, Research & Early Clin Dev) Sale 7,000 36.51 255,570
2013-07-30 Glaxosmithkline Plc Buy 3,064,407 111,850,855.50 342,756,544,550,188
2013-06-07 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 31,038 35.04 1,087,571
2013-05-29 Mammen Mathai (SVP, Research & Early Clin Dev) Option Ex 11,021 7.75 85,412
2013-05-29 Brinkley David L (Head of Business Dev.) Sale 3,808 35.01 133,318
2013-05-13 Brinkley David L (Head of Business Dev.) Sale 16,129 40.33 650,482
2013-05-13 Brinkley David L (Head of Business Dev.) Option Ex 16,129 34.00 548,386
2013-05-03 Brinkley David L (Head of Business Dev.) Sale 16,129 34.77 560,805
2013-05-03 Brinkley David L (Head of Business Dev.) Option Ex 16,129 29.65 478,224
2013-04-30 Mammen Mathai (SVP, Research & Early Clin Dev) Sale 7,000 34.03 238,210
2013-04-30 Aguiar Michael W (Sr VP, Chief Financial Officer) Sale 170,879 34.05 5,819,284
2013-04-30 Aguiar Michael W (Sr VP, Chief Financial Officer) Option Ex 170,879 17.91 3,060,442
2013-04-30 Brinkley David L (Head of Business Dev.) Sale 17,104 34.05 582,476
2013-04-30 Brinkley David L (Head of Business Dev.) Option Ex 8,333 6.15 51,247
2013-04-30 Winningham Rick E (Chief Executive Officer) Sale 255,532 33.98 8,682,977
2013-04-30 Winningham Rick E (Chief Executive Officer) Option Ex 385,161 9.69 3,731,439
2013-04-30 Glaxosmithkline Plc Buy 193,563 6,699,215.43 1,296,720,236,277
2013-02-20 Mammen Mathai (SVP, Research & Early Clin Dev) Sale 7,000 22.14 154,980
2013-02-15 Glaxosmithkline Plc Buy 116,527 2,567,089.81 299,135,274,289
2013-01-11 Mammen Mathai (SVP, Research & Early Clin Dev) Option Ex 14,510 3.10 44,981
2012-11-14 Mammen Mathai (SVP, Research & Early Clin Dev) Option Ex 5,161 3.10 15,999
2012-11-02 Mammen Mathai (SVP, Research & Early Clin Dev) Sale 7,000 21.98 153,825
2012-11-02 Glaxosmithkline Plc Buy 280,348 6,265,777.80 1,756,598,274,674
2012-08-27 Aguiar Michael W (Sr VP, Chief Financial Officer) Sale 20,561 27.55 566,455
2012-08-24 Aguiar Michael W (Sr VP, Chief Financial Officer) Sale 4,121 28.01 115,429
2012-08-24 Aguiar Michael W (Sr VP, Chief Financial Officer) Option Ex 4,121 17.91 73,807
2012-08-24 Brinkley David L (Head of Business Dev.) Sale 3,483 27.50 95,782
2012-08-13 Mammen Mathai (SVP, Research & Early Clin Dev) Sale 25,000 25.91 647,875
2012-08-07 Aguiar Michael W (Sr VP, Chief Financial Officer) Sale 60,000 27.04 1,622,400
2012-08-07 Aguiar Michael W (Sr VP, Chief Financial Officer) Option Ex 60,000 16.25 975,000
2012-08-03 Brinkley David L (Head of Business Dev.) Sale 123,917 27.92 3,459,762
2012-08-03 Brinkley David L (Head of Business Dev.) Option Ex 106,757 12.26 1,308,840
2012-08-03 Winningham Rick E (Chief Executive Officer) Sale 75,749 27.96 2,117,942
2012-08-03 Winningham Rick E (Chief Executive Officer) Option Ex 145,161 3.10 449,999
2012-08-03 Glaxosmithkline Plc Buy 316,334 28.21 8,923,782
2012-05-29 Aguiar Michael W (Sr VP, Chief Financial Officer) Sale 20,000 22.29 445,800
2012-05-16 Glaxosmithkline Plc Buy 10,000,000 21.29 212,890,000
2012-05-04 Winningham Rick E (Chief Executive Officer) Option Ex 63,225 6.39 404,323
2012-05-01 Drazan Jeffrey M Sale 8,586 21.71 186,402
2012-02-14 Glaxosmithkline Plc (10% Owner) Buy 88,468 18.12 1,603,040
2011-12-09 Aguiar Michael W (Sr VP, Chief Financial Officer) Sale 10,000 21.86 218,600
2011-11-28 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 20,000 21.00 420,000
2011-11-28 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Option Ex 30,205 8.53 257,648
2011-11-28 Drazan Jeffrey M Sale 4,293 21.00 90,153
2011-11-01 Glaxosmithkline Plc (10% Owner) Buy 58,411 22.23 1,298,476
2011-09-01 Mammen Mathai (SVP, Research & Early Clin Dev) Option Ex 3,225 8.53 27,493
2011-06-14 Aguiar Michael W (Sr VP, Chief Financial Officer) Sale 14,225 22.94 326,321
2011-06-07 Drazan Jeffrey M (Director) Sale 31,907 23.29 743,114
2011-06-06 Drazan Jeffrey M (Director) Sale 37,344 23.08 861,899
2011-05-31 Brinkley David L (Head of Business Dev.) Sale 51,500 25.65 1,320,975
2011-05-31 Brinkley David L (Head of Business Dev.) Option Ex 45,441 14.03 637,537
2011-05-27 Brinkley David L (Head of Business Dev.) Sale 57,812 25.31 1,463,221
2011-05-27 Brinkley David L (Head of Business Dev.) Option Ex 57,812 5.30 306,230
2011-05-11 Winningham Rick E (Chief Executive Officer) Sale 73,100 26.28 1,921,068
2011-05-10 Winningham Rick E (Chief Executive Officer) Sale 54,646 26.41 1,443,200
2011-05-03 Glaxosmithkline Plc Buy 261,299 25.60 6,689,254
2011-03-16 Brinkley David L (Head of Business Dev.) Sale 2,100 22.02 46,242
2011-03-16 Brinkley David L (Head of Business Dev.) Option Ex 2,100 3.10 6,510
2011-03-15 Brinkley David L (Head of Business Dev.) Sale 45,492 22.08 1,004,463
2011-03-15 Brinkley David L (Head of Business Dev.) Option Ex 45,492 4.91 223,365
2011-03-11 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 26,689 22.75 607,308
2011-03-07 Young William D Sale 5,376 22.31 119,938
2011-03-07 Young William D Option Ex 10,752 8.53 91,660
2011-03-01 Winningham Rick E (Chief Executive Officer) Sale 63,873 22.53 1,439,058
2011-02-28 Winningham Rick E (Chief Executive Officer) Sale 67,000 22.99 1,540,330
2011-02-28 Winningham Rick E (Chief Executive Officer) Option Ex 101,752 8.53 867,435
2011-02-25 Winningham Rick E (Chief Executive Officer) Sale 92,200 22.48 2,072,656
2011-02-25 Winningham Rick E (Chief Executive Officer) Option Ex 135,850 8.53 1,158,121
2011-02-24 Winningham Rick E (Chief Executive Officer) Sale 93,100 21.45 1,996,995
2011-02-24 Winningham Rick E (Chief Executive Officer) Option Ex 135,950 8.53 1,158,973
2011-02-23 Winningham Rick E (Chief Executive Officer) Sale 97,600 21.14 2,063,264
2011-02-23 Winningham Rick E (Chief Executive Officer) Option Ex 142,500 8.53 1,214,812
2011-02-22 Winningham Rick E (Chief Executive Officer) Sale 168,800 21.79 3,678,152
2011-02-22 Winningham Rick E (Chief Executive Officer) Option Ex 258,140 8.53 2,200,643
2011-02-18 Mammen Mathai (SVP, Research & Early Clin Dev) Sale 3,701 23.12 85,567
2011-02-18 Young William D Sale 5,376 23.22 124,830
2011-02-18 Young William D Option Ex 10,752 8.53 91,660
2011-02-18 Glaxosmithkline Plc Buy 152,278 23.70 3,608,988
2011-01-28 Mammen Mathai (SVP, Research & Early Clin Dev) Option Ex 9,838 8.53 83,868
2010-12-10 Young William D Sale 5,377 26.64 143,243
2010-12-10 Young William D Option Ex 10,754 8.53 91,677
2010-12-03 Aguiar Michael W (Sr VP, Chief Financial Officer) Sale 10,000 26.51 265,100
2010-12-01 Brinkley David L (Head of Business Dev.) Sale 20,000 25.07 501,400
2010-12-01 Brinkley David L (Head of Business Dev.) Option Ex 15,275 3.10 47,352
2010-11-29 Glaxosmithkline Plc (10% Owner) Buy 5,750,000 22.50 129,375,000
2010-09-14 Brinkley David L (Head of Business Dev.) Sale 1,980 15.12 29,937
2010-09-07 Mammen Mathai (SVP, Research & Early Clin Dev) Option Ex 6,451 8.53 54,994
2010-09-01 Mammen Mathai (SVP, Research & Early Clin Dev) Sale 4,416 12.84 56,701
2010-06-15 Brinkley David L (Head of Business Dev.) Sale 33,516 15.45 517,822
2010-06-15 Brinkley David L (Head of Business Dev.) Option Ex 33,516 8.53 285,723
2010-06-14 Brinkley David L (Head of Business Dev.) Sale 33,516 15.65 524,525
2010-06-14 Brinkley David L (Head of Business Dev.) Option Ex 33,516 8.53 285,723
2010-02-25 Blum Leonard M (Sr VP, Chief Comm. Officer) Buy 677 10.33 6,993
2010-02-25 Waltrip William H Option Ex 32,258 8.53 275,160
2010-02-24 Blum Leonard M (Sr VP, Chief Comm. Officer) Buy 12,025 10.48 126,022
2009-12-23 Vagelos P Roy Option Ex 200,000 8.53 1,705,999
2009-12-16 Brinkley David L (Head of Business Dev.) Sale 1,956 13.01 25,447
2009-09-15 Brinkley David L (Head of Business Dev.) Sale 9,000 17.86 160,704
2009-09-15 Brinkley David L (Head of Business Dev.) Option Ex 9,000 8.53 76,725
2008-07-30 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 34,676 15.97 553,671
2008-06-04 Kitt Michael (Sr. Vice President Development) Sale 15,000 13.04 195,570
2008-06-04 Kitt Michael (Sr. Vice President Development) Option Ex 15,000 8.53 127,875
2008-06-03 Kitt Michael (Sr. Vice President Development) Sale 1,300 13.06 16,975
2008-06-03 Kitt Michael (Sr. Vice President Development) Option Ex 1,300 5.81 7,555
2008-06-02 Kitt Michael (Sr. Vice President Development) Sale 3,700 13.01 48,148
2008-06-02 Kitt Michael (Sr. Vice President Development) Option Ex 3,700 3.10 11,470
2008-03-14 Vagelos P Roy Buy 25,000 10.22 255,862
2008-03-13 Vagelos P Roy Buy 24,000 10.52 252,360
2008-03-11 Winningham Rick E (Chief Executive Officer) Buy 20,000 10.44 208,860
2008-03-10 Blum Leonard M (Sr VP, Chief Comm. Officer) Buy 28,385 10.45 296,481
2007-12-14 Brinkley David L (Sr. VP Commercial Development) Sale 4,439 22.64 100,498
2007-12-10 Humphrey Patrick Pa (Executive VP Research) Option Ex 54,310 7.10 385,818
2007-10-31 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 25,000 25.00 625,000
2007-09-14 Brinkley David L (Sr. VP Commercial Development) Sale 3,623 27.64 100,154
2007-08-23 Kitt Michael (Sr. Vice President Development) Sale 10,000 30.01 300,100
2007-08-23 Kitt Michael (Sr. Vice President Development) Option Ex 10,000 8.53 85,250
2007-08-01 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Sale 25,000 26.07 650,153
2007-06-15 Brinkley David L (Sr. VP Commercial Development) Sale 2,986 33.59 100,287
2007-02-28 Brinkley David L (Sr. VP Commercial Development) Sale 3,100 31.94 99,014
2006-06-29 Kitt Michael (Sr. Vice President Development) Option Ex 8,008 3.10 24,824
2006-06-09 Kitt Michael (Sr. Vice President Development) Sale 16,129 24.15 389,614
2006-06-09 Kitt Michael (Sr. Vice President Development) Option Ex 14,999 3.10 46,496
2006-05-03 Shafer Bradford J (Sr VP, Gen. Counsel, Secretary) Option Ex 40,761 5.81 236,902
2006-05-02 Loewenthal Ronn Sale 10,645 28.47 303,020
2006-05-02 Loewenthal Ronn Option Ex 10,645 8.53 90,748
2005-12-13 Baker Julian Sale 33,840 21.11 714,362

Insider trading activities including stock purchases, stock sales, and option exercises of INVA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Theravance Inc (symbol INVA, CIK number 1080014) see the Securities and Exchange Commission (SEC) website.